The Mechanism of MicroRNAs Network in Alzheimer's Disease

Alzheimer Disease Clinical Trial

— MicroRNAs AD  

Official title:

Shanghai Mental Health Center

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05055310
• Other study ID #: 81571298
• Status: Completed
• Start date: October 2016
• Est. completion date: December 31, 2019

Study information

• Verified date: January 2021
• Source: Shanghai Mental Health Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

MicroRNAs network, such as MicRNA107 et al, regulate the pathology of Alzheimer's disease and the clinical validation in diagnosis AD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

• NIA-AA MCI due to AD clinical criteria for MCI due to AD

• NIA-AA AD clinical criteria for AD

Exclusion Criteria:

• Other type of dementia

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Diagnostic Test:
• MicRNAs test
plasma micRNAs concentration

Locations

Country	Name	City	State
China	Department of Psychogeriatrics,Shanghai Mental Health Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MicRNAs diagnosis validation for aMCI	MicRNAs concentration in plasma among three groups	5 years